Drugs that contain Oxymorphone Hydrochloride

1. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851482 ENDO PHARMS Method for making analgesics
Jul, 2029

(6 years from now)

US8871779 ENDO PHARMS Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
Nov, 2029

(7 years from now)

CN101395159A ENDO PHARMS Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
Dec, 2011

(10 years ago)

CN101652371A ENDO PHARMS Improved Method For Producing Analgesics
Jun, 2012

(10 years ago)

CN102391271A ENDO PHARMS Improved Method For Making Analgesics
Dec, 2019

(2 years ago)

CN102391271B ENDO PHARMS Improved Method For Producing Analgesics
Dec, 2019

(2 years ago)

EP1994034A2 ENDO PHARMS Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
Mar, 2027

(4 years from now)

EP1994034B1 ENDO PHARMS Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329216 ENDO PHARMS Oxymorphone controlled release formulations Feb, 2023

(4 months from now)

US8309112 ENDO PHARMS Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same Feb, 2023

(4 months from now)

US8309122 ENDO PHARMS Oxymorphone controlled release formulations Feb, 2023

(4 months from now)

US7276250 ENDO PHARMS Sustained release formulations of oxymorphone Feb, 2023

(4 months from now)

US8075872 ENDO PHARMS Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 ENDO PHARMS Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8114383 ENDO PHARMS Abuse-proofed dosage form Aug, 2024

(1 year, 10 months from now)

US8192722 ENDO PHARMS Abuse-proof dosage form Sep, 2025

(2 years from now)

US8808737 ENDO PHARMS Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment Jun, 2027

(4 years from now)

Treatment: Relief of moderate to severe pain; Dose modification for renal impairment

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.